Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2020 | IMbark study: imetelstat in R/R triple-negative myelofibrosis

Jean-Jacques Kiladjian • 11 Dec 2020

ASH 2020

Myelofibrosis Myeloproliferative Neoplasms Imetelstat

IMbark

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, Université de Paris, Paris, France, outlines the results of IMbark (NCT024226086), a Phase II study of imetelstat in relapsed/refractory (R/R) triple-negative (TN) myelofibrosis patients with history of previous Janus kinase inhibitor (JAKi) treatment. Encouraging clinical outcomes and overall survival suggests that treatment with imetelstat may overcome the poor results expected in TN patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Advisory boards: Novartis, BMS, Abbvie, Geron

Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more

Claire Harrison et al. • 11 Dec 2023

The growing role of combination approaches in MF & agents being explored

Jean-Jacques Kiladjian • 9 Oct 2023

The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs

Jean-Jacques Kiladjian • 13 Jun 2023

Ruxolitinib combinations in patients with myelofibrosis

Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023